CANbridge Announces Encouraging Development in Maralixibat/LIVMARLI in Rare Liver Disease
PFIC is included in the 121 Rare Disease List published in 2018 by Chinese authorities.
- PFIC is included in the 121 Rare Disease List published in 2018 by Chinese authorities.
- We congratulate Mirum on the trial success and look forward to continuing to work together to bring potential new treatments to rare liver disease patients in Greater China, said James Xue, Ph.D., CANbridge Founder, Chairman and CEO.
- CANbridge Pharmaceuticals Inc. (HKEX:1228) is a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies for rare disease and rare oncology.
- CANbridge has a differentiated drug portfolio, with three approved drugs and a pipeline of 11 assets, targeting prevalent rare disease and rare oncology indications that have unmet needs and significant market potential.